• Revenue: Q4 revenue slightly down by 1% year-over-year, full-year revenue decreased to $112.3 million from $113.3 million.

• Gross Margin: Improved to 58.9% for the full year, up from 53.7% in the previous year.

• Operating Income: Q4 GAAP operating income at $0.3 million, full-year adjusted operating income increased to $13.1 million.

• Net Loss: Q4 net loss widened to $(1.8) million, full-year net loss improved to $(3.4) million from $(9.5) million.

• Adjusted EBITDA: Q4 remained stable at $3.6 million, full-year rose to $14.6 million from $10.8 million.

• Debt Reduction: Reduced by $10.5 million during the year, with net leverage ratio improving from 4.0 to 2.3.

• Warning! GuruFocus has detected 3 Warning Signs with HBIO.

On March 7, 2024, Harvard Bioscience Inc (NASDAQ:HBIO) released its 8-K filing, announcing the financial results for the fourth quarter and the full year ended December 31, 2023. The company, a global developer, manufacturer, and seller of technologies for life science research and pre-clinical testing, faced a modest revenue decline in a challenging Asia-Pacific (APAC) market.

Despite a slight decrease in revenue, Harvard Bioscience saw a significant expansion in gross margin, attributed to an enhanced product portfolio and the discontinuation of certain products. The gross margin for the full year improved notably to 58.9% from 53.7% in the previous year. Operating income for the fourth quarter was reported at $0.3 million, a turnaround from a loss of $(0.5) million in the same quarter of the prior year. Adjusted operating income for the year increased to $13.1 million from $9.5 million.

However, the company reported a net loss of $(1.8) million for the fourth quarter, slightly worse than the $(1.7) million loss in the fourth quarter of the previous year. The full-year net loss showed improvement, narrowing to $(3.4) million from $(9.5) million, which included an unfavorable impact from unrealized losses on marketable securities.

Adjusted EBITDA for the fourth quarter was stable at $3.6 million, while the full-year adjusted EBITDA increased to $14.6 million from $10.8 million, reflecting the company's operational efficiency and cost management. Cash flow from operations was strong, with $14.0 million generated in the full year compared to $1.2 million in the previous year. Debt was significantly reduced by $10.5 million during the year, and the net leverage ratio improved from 4.0 to 2.3.

For the full year 2024, Harvard Bioscience expects flat to modest revenue growth, with a stronger second half anticipated due to new product commercializations and improvements in the Chinese market conditions. The company also projects further gross margin expansion to approximately 60% and an adjusted EBITDA margin improvement to the mid-teens.